Menu
Search
|

Menu

Close
X

Cidara Therapeutics Inc CDTX.OQ (NASDAQ Stock Exchange Global Market)

2.55 USD
-- (--)
As of Mar 19
chart
Previous Close 2.55
Open --
Volume --
3m Avg Volume 23,403
Today’s High --
Today’s Low --
52 Week High 6.95
52 Week Low 1.96
Shares Outstanding (mil) 27.82
Market Capitalization (mil) 70.93
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
EPS (USD)
FY18
-2.866
FY17
-3.202
FY16
-3.315
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
58.80
Price to Sales (TTM)
vs sector
--
8.99
Price to Book (MRQ)
vs sector
1.20
4.66
Price to Cash Flow (TTM)
vs sector
--
40.60
Total Debt to Equity (MRQ)
vs sector
16.79
17.49
LT Debt to Equity (MRQ)
vs sector
0.00
13.83
Return on Investment (TTM)
vs sector
-93.55
12.11
Return on Equity (TTM)
vs sector
-116.66
13.22

EXECUTIVE LEADERSHIP

Scott Rocklage
Chairman of the Board, Since 2013
Salary: --
Bonus: --
Jeffrey Stein
President, Chief Executive Officer, Principal Financial Officer, Director, Since 2018
Salary: $460,000.00
Bonus: --
James Levine
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, Since 2018
Salary: --
Bonus: --
Paul Daruwala
Chief Operating Officer, Since 2017
Salary: --
Bonus: --
Carmen Betancourt
Senior Vice President - Regulatory affairs and quality, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

6310 Nancy Ridge Dr Ste 101
SAN DIEGO   CA   92121-3209

Phone: +1858.7526170

Cidara Therapeutics Inc., is a clinical-stage biotechnology company focused on developing new anti-infectives. The Company’s lead product candidate is rezafungin acetate, which is a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. The Company is also leveraging its novel Cloudbreak platform to develop antibody-drug conjugates for the treatment of serious viral and Gram-negative bacterial infections. Cloudbreak is the immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens.

SPONSORED STORIES